Shafique Virani - 15 Sep 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Business Officer
Signature: /s/ Nathan Hatfield, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 15 Sep 2022
Net transactions value: -$122,535
Form type: 4
Filing time: 16 Sep 2022, 18:58:53 UTC
Previous filing: 17 Aug 2022
Next filing: 18 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Options Exercise	$11,100	+5,000	+5.1%	$2.22^*	103,773	15 Sep 2022	Direct	F1
transaction	RXRX	Class A Common Stock	Sale	$128,046	-9,600	-9.3%	$13.34	94,173	15 Sep 2022	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Sale	$5,589	-400	-0.42%	$13.97	93,773	15 Sep 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-0.76%	$0.000000	656,955	15 Sep 2022	Class A Common Stock	5,000	$2.22	Direct	F1, F4
holding	RXRX	Stock Option (Right to Buy)						80,450	15 Sep 2022	Class A Common Stock	0	$11.40	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						5,436	15 Sep 2022	Class A Common Stock	0	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person
F2	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.89 to $13.82 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.93 to $14.07 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.